Head-to-head · Cost-Efficiency Index
NextMeds vs SkinnyRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NextMeds
Shoppers who will call out and verify the exact price at checkout, given the site shows several different promo numbers at once.
Visit NextMedsSkinnyRx
Shoppers who have already decided on a long commitment and want the term priced openly rather than hidden behind an intake — not price-first shoppers comparing on the advertised figure.
Visit SkinnyRxThe verdict
NextMeds takes it, leading the Cost-Efficiency Index 74 to 71. NextMeds is a compounded-GLP-1 telehealth platform naming a real clinical group (Lion MD, led by two NPI-verifiable physicians) and six named compounding pharmacies — unusually transparent on that front. SkinnyRx still earns a C — Shoppers who have already decided on a long commitment and want the term priced openly rather than hidden behind an intake — not price-first shoppers comparing on the advertised figure.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NextMeds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NextMeds | SkinnyRx |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 71/100 |
| Semaglutide / mo | $79/mo (starting dose, promotional rate, compounded) | $349/mo month-to-month ($299 on 4 months, $249 on 6, $199 only on 12) |
| Tirzepatide / mo | $129/mo (starting dose, promotional rate, compounded) | $399/mo month-to-month ($349 on 4 months, $329 on 6, $299 only on 12) |
| Semaglutide / yr (modeled) | $948 | $4,188 |
| Tirzepatide / yr (modeled) | $1,548 | $4,788 |
| Coverage | All 50 states | Most states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #56 | #60 |
NextMeds
74/100Where the value is
- Names a real, NPI-verifiable clinical group (Lion MD: Dr. Ana Lisa Carr, Dr. Kelly Tenbrink) rather than an anonymous provider network
- Names six real compounding pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, Foothills) instead of one generic claim
- Claims and states 'We service all 50 states'
The tradeoffs
- The live site shows at least three different headline promo prices ($69/$79/$89 for semaglutide) concurrently or near-concurrently, with no clear single 'current' number — a real transparency problem
- Aggressive countdown-timer urgency tactics ('Price increases in...', 'OFFER ENDS AUGUST 10TH AT MIDNIGHT!') are used to pressure signup
SkinnyRx
71/100Where the value is
- A complete four-term ladder for both molecules is published rather than gated, so the cost of not committing is knowable before signup
- Both compounded molecules are offered, with the same term structure on each
- The twelve-month rate is genuinely low for the category if a year is a commitment you were going to make anyway
The tradeoffs
- The '$199/month' it advertises everywhere is the TWELVE-MONTH rung. The rate you can stop after a month is $349 — 75% higher — and the figure appears without that term attached
- An FDA warning letter is on public record against Lean Rx, Inc. dba SkinnyRx, issued 20 February 2026. We disclose it and we do not treat it as disqualifying
Regulatory note: the FDA issued a warning letter to Lean Rx, Inc. dba SkinnyRx in February 2026. We still list and link to SkinnyRx; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.